Rituximab and Pegfilgrastim in Treating Patients With Non-Hodgkin's Lymphoma
-
- STATUS
- Recruiting
-
- participants needed
- 40
-
- sponsor
- Roswell Park Cancer Institute
Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Pegfilgrastim may stimulate the immune system in different ways and stop cancer cells from growing. Giving rituximab together with pegfilgrastim may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with pegfilgrastim works in treating patients with non-Hodgkin's lymphoma.
Description
OBJECTIVES: Primary - Evaluate the safety of rituximab and pegfilgrastim in patients with untreated or relapsed/recurrent follicular lymphoma, small lymphocytic lymphoma, or marginal zone lymphoma. Secondary - Evaluate the efficacy (including overall response rate and durability of objective responses) of this regimen in these patients. - Evaluate functional and phenotypic characteristics of host neutrophils. - Evaluate changes of CD20 antigen expression and density of expression. - Evaluate changes in serum tumor necrosis factor (TNF), interferon alpha, and free radical levels. OUTLINE: Patients receive rituximab IV once a week in weeks 1, 3, 5, 7, 15, 23, 31, and 39 and pegfilgrastim subcutaneously 3 days before receiving rituximab for a total of 8 doses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically during study treatment for correlative studies. Samples are analyzed for phenotype changes in neutrophils, oxidative burst, and cytokine levels by flow cytometry and in vitro functional assays. Patients with easily accessible lymphomatous lesions undergo excisional biopsy within 24 hours after completion of first dose of rituximab. Tissues are analyzed for infiltration of neutrophils into tumor bed, changes in CD20 expression by immunohistochemistry, flow cytometry, and western blot, and evidence of apoptosis. After completion of study treatment, patients are followed every 4 months for 1 year, every 6 months for 2 years, and once at year 4.
Details
| Condition | Lymphoma |
|---|---|
| Treatment | Rituximab, flow cytometry, immunohistochemistry staining method, pegfilgrastim |
| Clinical Study Identifier | NCT00524628 |
| Sponsor | Roswell Park Cancer Institute |
| Last Modified on | 7 November 2020 |
Eligibility
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer